Park Avenue Securities LLC Biomarin Pharmaceutical Inc Transaction History

Park Avenue Securities LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 09, 2024	SELL	$74.43 - $92.22 $139,184 - $172,451	-1,870 Reduced 40.48%	2,750 $226,000
Q1 2024 Apr 10, 2024	SELL	$83.81 - $99.0 $132,252 - $156,222	-1,578 Reduced 25.46%	4,620 $403,000
Q4 2023 Jan 10, 2024	BUY	$76.22 - $98.51 $85,137 - $110,035	1,117 Added 21.98%	6,198 $598,000
Q3 2023 Oct 26, 2023	BUY	$85.07 - $94.48 $432,240 - $480,052	5,081 New	5,081 $450,000
Q4 2022 Jan 24, 2023	SELL	$80.93 - $108.63 $890 - $1,194	-11 Reduced 0.43%	2,560 $0
Q3 2022 Nov 01, 2022	BUY	$82.16 - $96.94 $211,233 - $249,232	2,571 New	2,571 $217,000
Q3 2020 Nov 03, 2020	SELL	$71.87 - $131.03 $121,747 - $221,964	-1,694 Closed	0 $0
Q2 2020 Jul 30, 2020	BUY	$79.55 - $124.22 $134,757 - $210,428	1,694 New	1,694 $209,000

635

178M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $11.8B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Park Avenue Securities LLC, based on Form 13F filings with the SEC.

Stay updated on Park Avenue Securities LLC with notifications on news.